Mizuho Securities Reiterates Buy Rating on Fate Therapeutics (FATE), Analyst Sees Opportunity for Shares to Reprice
Tweet Send to a Friend
Mizuho Securities analyst Mara Goldstein reiterated a Buy rating and $109.00 price target on Fate Therapeutics (NASDAQ: FATE)The analyst quotes ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
